Cardiac cachexia is the wasting of muscle and other tissue that develops in advanced heart failure, and it is the reason a cardiology team weighs a patient who is already retaining fluid.
Key takeaways
- The working definition is non-oedematous weight loss of at least 6% of previous body weight within the past 6 to 12 months in a patient with heart failure.
- The word non-oedematous carries the whole diagnostic difficulty. Fluid retention can hold the scale steady while lean tissue is disappearing.
- A 2022 review in Cardiology Clinics puts the frequency at roughly 10% to 39% of heart failure patients, concentrated in advanced disease and in congestive right ventricular dysfunction.
- In the study that established its prognostic weight, wasting predicted 18-month mortality independently of age, NYHA class, ejection fraction and peak oxygen consumption.
- This is a marker of a systemic process, not simply of poor eating, which is why increasing calories does not reliably reverse it.
How cardiac cachexia is defined
Cardiac cachexia is not a synonym for looking thin at a heart failure clinic. It is a defined co-morbidity with a threshold attached.
The definition used in the current cardiology literature is non-oedematous weight loss of at least 6% within the previous 6 to 12 months, set out in a 2022 Cardiology Clinics review by Valentova, Anker and von Haehling. That figure is not arbitrary. It sits downstream of decades of work establishing that beyond a certain amount of unintentional loss, the trajectory of a heart failure patient changes.
The threshold has moved. The original prospective study, published in the Lancet in 1997, defined the cachectic state as non-intentional documented weight loss of at least 7.5% of previous normal weight over at least six months. The later 6% figure is the one in general use now, and the direction of travel is toward catching the process earlier.
Underneath the cardiology-specific number sits the general cachexia definition agreed by consensus in 2008: a complex metabolic syndrome associated with underlying illness, characterised by loss of muscle with or without loss of fat mass, and explicitly distinct from starvation.
Why oedema makes it hard to see
Every published definition specifies non-oedematous loss, and that qualifier is where the clinical difficulty lives.
Heart failure causes fluid to accumulate in the legs, the abdomen and the lungs. A patient can be losing muscle steadily while gaining fluid at a similar rate, and the bathroom scale reports nothing at all. The number that matters is dry weight, which is the weight at a stable, decongested fluid status, and it is only interpretable if someone has been tracking it consistently.
This is why cachexia in heart failure is often noticed late, and often noticed after a diuresis, when the fluid comes off and the loss underneath it becomes visible in one step. It is also why serial dry weights, and not a single reading, are the useful measurement.
The same problem runs through the general cachexia literature. The 2008 consensus statement specifies weight loss corrected for fluid retention for exactly this reason, and heart failure is the setting where the correction matters most.
How often it happens
The 2022 Cardiology Clinics review reports that cachexia affects roughly 10% to 39% of patients with heart failure. That is a wide band, and the width is informative rather than sloppy: it reflects genuine differences between cohorts in disease severity, in the definition applied, and in how carefully dry weight was tracked.
The review is more specific about where those patients sit. Cachexia occurs typically in advanced stages of heart failure, and particularly in the presence of congestive right ventricular dysfunction. Right-sided congestion is the setting that produces venous congestion of the gut and the liver, which is one of the mechanisms most often implicated in the wasting itself.
What the outcome data show
The reason cardiac cachexia gets attention at all is a single well-designed prospective study.
Anker and colleagues followed 171 consecutive patients with chronic heart failure between 1993 and 1995, defining cachectic status prospectively rather than retrospectively. Twenty-eight patients met the definition. In that cohort, mortality among the cachectic patients was 18% at 3 months, 29% at 6 months, 39% at 12 months and 50% at 18 months.
The finding that mattered was not the raw mortality but its independence. The cachectic state predicted 18-month mortality independently of age, NYHA functional class, left ventricular ejection fraction and peak oxygen consumption. In other words, knowing a patient had wasted told you something the standard prognostic markers did not.
Combining the two markers sharpened it further. Among patients with both cachexia and a peak oxygen consumption below 14 mL/kg/min, 18-month survival was 23%, against 93% in patients with neither risk factor.
Those figures come from a single centre in the mid-1990s, and heart failure therapy has changed substantially since. The specific percentages should be read as historical rather than as what a patient should expect today. What has held up is the structural finding: unintentional wasting carries prognostic information of its own.
What drives the wasting
Cardiac cachexia is not caused by one thing, which is a large part of why it is hard to treat.
The mechanisms described in the heart failure literature run in parallel. Neurohormonal activation, meaning sustained sympathetic nervous system and renin-angiotensin-aldosterone system drive, pushes the body toward a catabolic state. Systemic inflammation is characteristic of advanced heart failure and is associated with muscle protein breakdown. Venous congestion of the gut impairs absorption and contributes to anorexia and early satiety, so intake falls at the same time as requirements rise. Reduced physical activity removes the main stimulus for maintaining muscle. Insulin resistance blunts the anabolic response to whatever food does get eaten.
Each of those alone would be manageable. Running together, in a patient whose exercise capacity is already limited, they produce a net loss that eating more does not close.
What clinical teams actually do
There is no approved drug that reverses cardiac cachexia, and no nutritional protocol that reliably restores lost muscle in advanced heart failure.
What clinical practice centres on is optimising heart failure treatment itself, tracking dry weight over time rather than reacting to single readings, screening for and correcting contributing problems such as poor intake and micronutrient deficiency, and maintaining physical activity or supervised cardiac rehabilitation where a patient can tolerate it. The wasting is a manifestation of the underlying disease state, so the underlying disease state is where the leverage is.
Anyone reading this about themselves or a family member should take documented unintentional weight loss to the heart failure team rather than to a supplement aisle. It is a piece of clinical information, and it changes how a case is assessed.
How cardiac cachexia is coded
For medical coders, this is a two-code situation rather than a one-code situation.
Cachexia attributed to a documented underlying condition is reported with E88.A, wasting disease due to underlying condition, with the heart failure code sequenced first. R64 covers cachexia recorded without a documented underlying cause, and the two carry an Excludes1 relationship, meaning they are never reported together. Our cachexia ICD-10 guide works through the documentation requirements in detail.
Where myostatin fits
Heart failure is one of the more interesting settings for myostatin biology, because the failing heart is not a passive bystander in the wasting of skeletal muscle.
Myostatin, or GDF-8, is a TGF-beta family protein that restrains skeletal muscle growth, and it is expressed in cardiac as well as skeletal muscle. The proposition explored in the research literature is that a failing heart contributes to the circulating pool, and that skeletal muscle elsewhere in the body absorbs the consequences. That would make cardiac cachexia partly a signalling problem rather than purely a nutritional or perfusion problem.
We work through that evidence, the prognostic data on circulating myostatin, and why blocking the pathway in cardiac patients is more complicated than it sounds, in myostatin and heart failure. The parallel story in oncology is covered in myostatin and cancer cachexia. Neither pathway has produced an approved therapy for wasting in heart failure.
Sources
- Valentova M, Anker SD, von Haehling S. Cardiac cachexia revisited: the role of wasting in heart failure. Cardiology Clinics. 2022;40(2):199-207.
- Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349(9058):1050-1053.
- Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clinical Nutrition. 2008;27(6):793-799.
- ICD-10-CM code E88.A, Wasting disease (syndrome) due to underlying condition, AAPC Codify.
Frequently asked questions
What weight loss counts as cardiac cachexia?
The definition used in current cardiology practice is non-oedematous weight loss of at least 6% of previous body weight within the past 6 to 12 months, in a patient with heart failure and without another explanation such as intentional dieting. The original 1997 prospective study used a stricter 7.5% threshold over at least six months.
Why does the definition say non-oedematous?
Because fluid retention can conceal the loss completely. A patient losing muscle while accumulating oedema may show a stable or even rising weight. The measurement that counts is dry weight, taken at a stable decongested fluid status and tracked over time, which is why a single reading cannot establish or exclude the diagnosis.
How common is cachexia in heart failure?
A 2022 review in Cardiology Clinics reports roughly 10% to 39% of heart failure patients, with the range reflecting differences in cohort severity and in the definition applied. It clusters in advanced heart failure and particularly where there is congestive right ventricular dysfunction.
Does cardiac cachexia mean the prognosis is poor?
It is an independent adverse prognostic marker. In the 1997 Lancet cohort, cachectic status predicted 18-month mortality independently of age, NYHA class, ejection fraction and peak oxygen consumption. Those specific percentages come from a single centre in the mid-1990s and predate much of modern heart failure therapy, so they describe the strength of the signal rather than an individual outlook. Prognosis for any particular patient is a question for the treating team.
Can eating more reverse it?
Not reliably. Cachexia is defined in part by the fact that conventional nutritional support does not fully reverse it, because the loss is driven by inflammation, neurohormonal activation, insulin resistance and impaired gut absorption rather than by insufficient intake. Nutrition remains supportive care rather than a cure, and nutritional plans in heart failure need clinical supervision because fluid and sodium targets are involved.
This article is for educational purposes only and is not medical advice. Cardiac cachexia is a clinical diagnosis that requires assessment by a qualified healthcare professional, and unintentional weight loss in heart failure should be reported to the treating team. Do not change diet, fluid intake, sodium intake, exercise or any medication on the basis of this page.